

Vivencio Barrios

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/543523/publications.pdf>

Version: 2024-02-01

129
papers

1,528
citations

430442

18
h-index

377514

34
g-index

140
all docs

140
docs citations

140
times ranked

1506
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Pacientes con fibrilaci3n auricular asistidos en consultas de atenci3n primaria. Estudio Val-FAAP. Revista Espanola De Cardiologia, 2012, 65, 47-53. | 0.6 | 162 |
| 2 | Control de la anticoagulaci3n en pacientes con fibrilaci3n auricular no valvular asistidos en atenci3n primaria en EspaA±a. Estudio PAULA. Revista Espanola De Cardiologia, 2015, 68, 769-776. | 0.6 | 118 |
| 3 | A nutraceutical approach (Armolidip Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: Review of the clinical evidence. Atherosclerosis Supplements, 2017, 24, 1-15. | 1.2 | 83 |
| 4 | Mid-term outcome of severe tricuspid regurgitation: are there any differences according to mechanism and severity?. European Heart Journal Cardiovascular Imaging, 2019, 20, 1035-1042. | 0.5 | 66 |
| 5 | Antihypertensive Efficacy and Tolerability of Lercanidipine in Daily Clinical Practice. The ELYPSE Study. Blood Pressure, 2002, 11, 95-100. | 0.7 | 54 |
| 6 | Blood Pressure and Lipid Goal Attainment in the Hypertensive Population in the Primary Care Setting in Spain. Journal of Clinical Hypertension, 2007, 9, 324-329. | 1.0 | 41 |
| 7 | Olmesartan Medoxomil plus Amlodipine Increases Efficacy in Patients with Moderate-to-Severe Hypertension after Monotherapy. Clinical Drug Investigation, 2009, 29, 427-439. | 1.1 | 41 |
| 8 | Rivaroxaban: a once-daily anticoagulant for the prevention of thromboembolic complications. Expert Review of Cardiovascular Therapy, 2013, 11, 129-141. | 0.6 | 36 |
| 9 | Efficacy and Tolerability of Olmesartan Medoxomil in Patients??with Mild to Moderate Essential Hypertension. Clinical Drug Investigation, 2007, 27, 545-558. | 1.1 | 35 |
| 10 | N -Acetylcysteine Potentiates the Antihypertensive Effect of ACE Inhibitors in Hypertensive Patients. Blood Pressure, 2002, 11, 235-239. | 0.7 | 34 |
| 11 | Prevalence of the Metabolic Syndrome in Patients With Hypertension Treated in General Practice in Spain: An Assessment of Blood Pressure and Low-Density Lipoprotein Cholesterol Control and Accuracy of Diagnosis. Journal of the Cardiometabolic Syndrome, 2007, 2, 9-15. | 1.7 | 31 |
| 12 | Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in daily clinical practice: the SARA study. Journal of Hypertension, 2007, 25, 1967-1973. | 0.3 | 27 |
| 13 | Anticoagulation Control in Patients With Nonvalvular Atrial Fibrillation Attended at Primary Care Centers in Spain: The PAULA Study. Revista Espanola De Cardiologia (English Ed), 2015, 68, 769-776. | 0.4 | 26 |
| 14 | Evaluation of SAME-TT₂_R₂ score and other clinical factors influencing the quality of anticoagulation therapy in non-valvular atrial fibrillation: a nationwide study in Spain. Current Medical Research and Opinion, 2016, 32, 1201-1207. | 0.9 | 24 |
| 15 | Sex Differences in the Hypertensive Population With Chronic Ischemic Heart Disease. Journal of Clinical Hypertension, 2008, 10, 779-786. | 1.0 | 19 |
| 16 | Clinical profile and management of hypertensive patients with chronic ischemic heart disease and renal dysfunction attended by cardiologists in daily clinical practice. Journal of Hypertension, 2008, 26, 2230-2235. | 0.3 | 19 |
| 17 | COSMIC project: consensus on the objectives of the metabolic syndrome in clinic. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2018, Volume 11, 683-697. | 1.1 | 19 |
| 18 | Regression of left ventricular hypertrophy by a candesartan-based regimen in clinical practice The VIPE study. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2006, 7, 236-242. | 1.0 | 18 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Prevalence of left ventricular hypertrophy detected by Cornell voltageâ€duration product in a hypertensive population. <i>Blood Pressure</i> , 2008, 17, 110-115. | 0.7 | 18 |
| 20 | Lipid management across Europe in the real-world setting: a rapid evidence review. <i>Current Medical Research and Opinion</i> , 2021, 37, 2049-2059. | 0.9 | 18 |
| 21 | Control de la anticoagulaci3n con warfarina o acenocumarol enÂEspaÃ±a. Â¿HayÂdiferencias?. <i>Revista Espanola De Cardiologia</i> , 2015, 68, 1181-1182. | 0.6 | 17 |
| 22 | Atrial fibrillation and chronic kidney disease: focus on rivaroxaban. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 651-664. | 0.6 | 17 |
| 23 | Fixed combinations in the management of hypertension: perspectives on lercanidipine – enalapril. <i>Vascular Health and Risk Management</i> , 2008, Volume 4, 847-853. | 1.0 | 16 |
| 24 | Telemedicine consultation for the clinical cardiologists in the era of COVID-19: present and future. Consensus document of the Spanish Society of Cardiology. <i>Revista Espanola De Cardiologia (English)</i> Tj ETQq0 0 0ogBT /Overlock 10 Tf | | |
| 25 | Clinical Profile and Management of Patients With Hypertension and Chronic Ischemic Heart Disease According to BMI. <i>Obesity</i> , 2010, 18, 2017-2022. | 1.5 | 15 |
| 26 | Thromboembolic and bleeding events with rivaroxaban in clinical practice in Spain: impact of inappropriate doses (the EMIR study). <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 583-593. | 0.6 | 15 |
| 27 | Gender differences in the diagnosis and treatment of left ventricular hypertrophy detected by different electrocardiographic criteria. Findings from the SARA study. <i>Heart and Vessels</i> , 2010, 25, 51-56. | 0.5 | 14 |
| 28 | SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucoseâ€lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review. <i>Diabetic Medicine</i> , 2021, 38, e14502. | 1.2 | 14 |
| 29 | Usefulness of a Cardiovascular Polypill in the Treatment of Secondary Prevention Patients in Spain: A Cost-effectiveness Study. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 42-49. | 0.4 | 13 |
| 30 | Olmesartan medoxomil plus hydrochlorothiazide for treating hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 129-136. | 0.9 | 12 |
| 31 | Rosuvastatin along the cardiovascular continuum: from JUPITER to AURORA. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 1317-1327. | 0.6 | 12 |
| 32 | Detection of unrecognized clinical heart failure in elderly hypertensive women attended in primary care setting. <i>Blood Pressure</i> , 2010, 19, 301-307. | 0.7 | 12 |
| 33 | Aliskiren in the Management of Hypertension. <i>American Journal of Cardiovascular Drugs</i> , 2010, 10, 349-358. | 1.0 | 12 |
| 34 | Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain. <i>Journal of Medical Economics</i> , 2012, 15, 45-54. | 1.0 | 11 |
| 35 | Which thiazide to choose as add-on therapy for hypertension?. <i>Integrated Blood Pressure Control</i> , 2014, 7, 35. | 0.4 | 11 |
| 36 | Use of Antithrombotic Therapy According to CHA2DS2-VASc Score in Patients With Atrial Fibrillation in Primary Care. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014, 67, 150-151. | 0.4 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Clinical benefits of pitavastatin: focus on patients with diabetes or at risk of developing diabetes. <i>Future Cardiology</i> , 2016, 12, 449-466. | 0.5 | 11 |
| 38 | Therapeutic behavior of primary care physicians in patients with atrial fibrillation taking vitamin K antagonists not adequately controlled. <i>European Journal of Internal Medicine</i> , 2016, 30, e17-e18. | 1.0 | 11 |
| 39 | Rivaroxaban: searching the integral vascular protection. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 719-728. | 1.3 | 11 |
| 40 | Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with diabetes: data from the SARA study. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2009, 10, 168-173. | 1.0 | 10 |
| 41 | Clinical profile and management of patients with chronic ischemic heart disease according to age in the population daily attended by cardiologists in Spain. <i>European Journal of Internal Medicine</i> , 2010, 21, 180-184. | 1.0 | 10 |
| 42 | Recommendations to improve lipid control. Consensus document of the Spanish Society of Cardiology. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 161-167. | 0.4 | 10 |
| 43 | Tolerability of High Doses of Lercanidipine versus High Doses of Other Dihydropyridines in Daily Clinical Practice: The TOLERANCE Study. <i>Cardiovascular Drug Reviews</i> , 2008, 26, 2-9. | 4.4 | 9 |
| 44 | Edoxaban for the prevention of stroke in patients with atrial fibrillation. <i>Expert Review of Cardiovascular Therapy</i> , 2019, 17, 319-330. | 0.6 | 9 |
| 45 | Utilization of sacubitril/valsartan in patients with heart failure with reduced ejection fraction: real-world data from the ARIADNE registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 469-477. | 1.8 | 9 |
| 46 | Assessment of medical management in Coronary Type 2 Diabetic patients with previous percutaneous coronary intervention in Spain: A retrospective analysis of electronic health records using Natural Language Processing. <i>PLoS ONE</i> , 2022, 17, e0263277. | 1.1 | 9 |
| 47 | Clinical applicability of B-type natriuretic peptide in patients with suspected heart failure in primary care in Spain: the PANAMA study. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 579-585. | 0.6 | 8 |
| 48 | New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 2649-2661. | 0.9 | 8 |
| 49 | Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in clinical practice. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 159-166. | 0.6 | 8 |
| 50 | Prevalence of renal dysfunction according to the type of atrial fibrillation and anticoagulation treatment in patients who attended primary care in Spain. <i>Future Cardiology</i> , 2014, 10, 215-220. | 0.5 | 8 |
| 51 | Candesartan in the treatment of hypertension: what have we learnt in the last decade?. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 957-968. | 1.0 | 7 |
| 52 | Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker?. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 2249-2261. | 0.9 | 7 |
| 53 | Importance of medication adherence from the ONTARGET and TRANSCEND points of view. <i>Fundamental and Clinical Pharmacology</i> , 2009, 23, 259-260. | 1.0 | 6 |
| 54 | Complementary mechanisms of action and rationale for the fixed combination of perindopril and indapamide in treating hypertension – update on clinical utility. <i>Integrated Blood Pressure Control</i> , 2010, 3, 11. | 0.4 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Antihypertensive and organ-protective effects of benazepril. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 1653-1671. | 0.6 | 6 |
| 56 | Edoxaban in the prevention and treatment of thromboembolic complications from a clinical point of view. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 811-824. | 0.6 | 6 |
| 57 | Control of Anticoagulation With Warfarin or Acenocoumarol in Spain. Do They Differ?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 1181-1182. | 0.4 | 6 |
| 58 | Improving cardiovascular protection: focus on a cardiovascular polypill. <i>Future Cardiology</i> , 2016, 12, 181-196. | 0.5 | 6 |
| 59 | Influence of renal function on anticoagulation control in patients with non-valvular atrial fibrillation taking vitamin K antagonists. <i>International Journal of Clinical Practice</i> , 2017, 71, e12974. | 0.8 | 6 |
| 60 | Blood pressure goal achievement with olmesartan medoxomil-based treatment: additional analysis of the OLMEBEST study. <i>Vascular Health and Risk Management</i> , 2009, 5, 723. | 1.0 | 5 |
| 61 | Valsartanâ€“amlodipineâ€“hydrochlorothiazide: the definitive fixed combination?. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 1609-1618. | 0.6 | 5 |
| 62 | Clinical Cardiology, Geriatric Cardiology, Heart Failure, and Transplantation 2015: A Selection of Topical Issues. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 159-166. | 0.4 | 5 |
| 63 | Switching to sacubitril/valsartan or adding aldosterone antagonist: which first?. <i>ESC Heart Failure</i> , 2019, 6, 1334-1335. | 1.4 | 5 |
| 64 | Canagliflozin: metabolic, cardiovascular and renal protection. <i>Future Cardiology</i> , 2021, 17, 443-458. | 0.5 | 5 |
| 65 | Rosuvastatin and Diabetes: When the Evidences Talk. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2013, 11, 115-124. | 0.4 | 5 |
| 66 | Perception of Patients Regarding Burdens and Benefits of Vitamin K Antagonists Among Patients with Nonvalvular Atrial Fibrillation. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2019, 16, 106-113. | 0.4 | 5 |
| 67 | Effectiveness and Safety of Dabigatran Compared to Vitamin K Antagonists in Non-Asian Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis. <i>Clinical Drug Investigation</i> , 2021, 41, 941-953. | 1.1 | 5 |
| 68 | Use of rivaroxaban attenuates renal function impairment in patients with atrial fibrillation: insights of the EMIR study. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13788. | 1.7 | 5 |
| 69 | Low-dose fixed combination of perindopril plus indapamide in the diabetic hypertensive population. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 1063-1069. | 0.6 | 4 |
| 70 | Aliskiren: A New Drug for an Old Problem. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2010, 8, 1-10. | 0.4 | 4 |
| 71 | Clinical Profile and Blood Pressure Control in Patients Managed in Primary Care in Spain: Are There any Differences Between the Young and the Old?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2013, 66, 824-825. | 0.4 | 4 |
| 72 | Dabigatran and Bleeding Risk: The Importance of a Correct Prescription. <i>Journal of Emergency Medicine</i> , 2014, 46, 831-832. | 0.3 | 4 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Implications of edoxaban in the prevention and treatment of thromboembolic complications in clinical practice. <i>Future Cardiology</i> , 2016, 12, 419-433. | 0.5 | 4 |
| 74 | Vaccination in Patients With Heart Disease. How Long Should We Wait?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 515. | 0.4 | 4 |
| 75 | Recommendations to improve the management and the prognosis of patients with heart failure. <i>Future Cardiology</i> , 2020, 16, 1-4. | 0.5 | 4 |
| 76 | Role of telemedicine in the management of oral anticoagulation in atrial fibrillation: a practical clinical approach. <i>Future Cardiology</i> , 0, , . | 0.5 | 4 |
| 77 | Beating the clock: reducing cardiovascular risk by rapid blood pressure reduction with olmesartan. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1549-1558. | 0.9 | 3 |
| 78 | Blood pressure control in anticoagulated patients with hypertension and atrial fibrillation. <i>Blood Pressure</i> , 2017, 26, 279-283. | 0.7 | 3 |
| 79 | Diabetes mellitus and cardiovascular clinical characteristics of Spanish women with stable ischaemic heart disease: Data from the SIRENA study. <i>Diabetes Research and Clinical Practice</i> , 2017, 123, 82-86. | 1.1 | 3 |
| 80 | Atrial fibrillation, an equivalent of cardiovascular disease risk. <i>European Heart Journal</i> , 2020, 41, 4599-4599. | 1.0 | 3 |
| 81 | Prevalence of office and ambulatory hypotension in treated hypertensive patients with coronary disease. <i>Hypertension Research</i> , 2020, 43, 696-704. | 1.5 | 3 |
| 82 | Chronic Coronary Syndrome: Overcoming Clinical Practice Guidelines. The role of the COMPASS Strategy. <i>Current Cardiology Reviews</i> , 2021, 17, 294-305. | 0.6 | 3 |
| 83 | Moving from the stratification of primary and secondary prevention of cardiovascular risk in diabetes towards a continuum of risk: need for a new paradigm. <i>Drugs in Context</i> , 2021, 10, 1-3. | 1.0 | 3 |
| 84 | Candesartan: from left ventricular hypertrophy to heart failure, a global approach. <i>Expert Review of Cardiovascular Therapy</i> , 2007, 5, 825-834. | 0.6 | 2 |
| 85 | Pulse Pressure and the Metabolic Syndrome in Patients With Hypertension. <i>Journal of the Cardiometabolic Syndrome</i> , 2009, 4, 72-75. | 1.7 | 2 |
| 86 | Update on Heart Failure, Heart Transplant, Congenital Heart Disease, and Clinical Cardiology. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2013, 66, 290-297. | 0.4 | 2 |
| 87 | Puntuaci3n SAMe-TT2R2:  jes  til en todos los pacientes con  fibrilaci3n auricular no  valvular?. <i>Revista Espanola De Cardiologia</i> , 2016, 69, 798. | 0.6 | 2 |
| 88 | Why Should We Recommend Pneumococcal Vaccine in Patients With Chronic Heart Diseases?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2018, 71, 57-58. | 0.4 | 2 |
| 89 | Patients ™ perceptions with dabigatran in patients with atrial fibrillation previously treated with vitamin K antagonists. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 615-625. | 0.6 | 2 |
| 90 | Metformin in the era of new antidiabetics. <i>Future Cardiology</i> , 2021, 17, 475-485. | 0.5 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Análisis del proceso de prescripción de inhibidores PCSK9 en los servicios de cardiología de los hospitales españoles y propuesta de optimización. Estudio IKIGAI. Clínica E Investigación En Arteriosclerosis, 2021, 33, 296-305. | 0.4 | 2 |
| 92 | Primary prevention. The cornerstone to reduce the burden of cardiovascular disease. Revista Española De Cardiología (English Ed), 2021, 74, 827-828. | 0.4 | 2 |
| 93 | Association of the KDIGO Risk Classification with the Prevalence of Heart Failure in Patients with Type 2 Diabetes. Journal of Clinical Medicine, 2021, 10, 4634. | 1.0 | 2 |
| 94 | Risk Factors Control in Diabetes. The Diabetes Educator, 2008, 34, 763-764. | 2.6 | 1 |
| 95 | Arrhythmogenic Right Ventricular Dysplasia. Journal of the American College of Cardiology, 2009, 53, 295. | 1.2 | 1 |
| 96 | Diltiazem in the treatment of hypertension and ischemic heart disease. Expert Review of Cardiovascular Therapy, 2011, 9, 1375-1382. | 0.6 | 1 |
| 97 | Can dabigatran improve blood pressure control?. Future Cardiology, 2013, 9, 321-323. | 0.5 | 1 |
| 98 | Selection of the Best of 2016 in Diabetes and Heart. Revista Española De Cardiología (English Ed), 2017, 70, 124-125. | 0.4 | 1 |
| 99 | Use of direct oral anticoagulants in patients with nonvalvular atrial fibrillation according to clinical profile. Future Cardiology, 2017, 13, 49-64. | 0.5 | 1 |
| 100 | Selection of the Best of 2017 in Clinical Cardiology. Therapeutic Novelties. Revista Española De Cardiología (English Ed), 2018, 71, 60. | 0.4 | 1 |
| 101 | Cost and burden of poor anticoagulation control with vitamin K antagonists in patients with nonvalvular atrial fibrillation in Spain. Revista Española De Cardiología (English Ed), 2020, 74, 773-780. | 0.4 | 1 |
| 102 | Primer registro nacional sobre la efectividad y seguridad de evolocumab en la práctica clínica en pacientes atendidos en cardiología en España. Estudio RETOSS-CARDIO. Clínica E Investigación En Arteriosclerosis, 2020, 32, 231-241. | 0.4 | 1 |
| 103 | Revisiting Hypertension in Rural Areas: A New Approach Is Required. American Journal of Hypertension, 2021, 34, 910-911. | 1.0 | 1 |
| 104 | May we apply results data from classical hypertension clinical trials to all beta-blockers?. Journal of Hypertension, 2020, 38, 2544. | 0.3 | 1 |
| 105 | Atrial Fibrillation And Coronary Heart Disease:Fatal Attraction. Journal of Atrial Fibrillation, 2009, 1, 137. | 0.5 | 1 |
| 106 | Lercanidipine improves its antihypertensive effectiveness with no impairment on its good tolerability profile in higher-risk hypertensives. the laura study. American Journal of Hypertension, 2004, 17, S100. | 1.0 | 0 |
| 107 | When the Clinical Trials Raise More Questions Than Answers: Blood Pressure Controversy Beyond the TRANSCEND Results. Journal of Clinical Hypertension, 2009, 11, 159-160. | 1.0 | 0 |
| 108 | The Heart of Revista Clínica Española, 2012. Revista Española De Cardiología (English Ed), 2013, 66, 677-678. | 0.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | El corazón de Revista Clínica Española, 2012. Revista Española De Cardiología, 2013, 66, 677-678. | 0.6 | 0 |
| 110 | Use of Antithrombotic Therapy in Patients With Atrial Fibrillation in Primary Care. Importance of INR Control. Response. Revista Española De Cardiología (English Ed), 2014, 67, 420. | 0.4 | 0 |
| 111 | Does CHA2DS2-VASc Score Select Patients Who Will Benefit Most From Anticoagulation? Response. Revista Española De Cardiología (English Ed), 2014, 67, 418. | 0.4 | 0 |
| 112 | Antihypertensive Medication: On the Right Path?. Revista Española De Cardiología (English Ed), 2015, 68, 1191. | 0.4 | 0 |
| 113 | Letter by Escobar et al Regarding Article, "On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF" Circulation, 2016, 134, e530-e531. | 1.6 | 0 |
| 114 | Degree of Anticoagulation Control in Patients With Atrial Fibrillation in Spain: Need to Minimize Biases and Contextualize Results. Response Barrios et al. Revista Española De Cardiología (English Ed), 2016, 69, 356-357. | 0.4 | 0 |
| 115 | SAMe-TT2R2 Score: Useful in All Patients With Nonvalvular Atrial Fibrillation?. Revista Española De Cardiología (English Ed), 2016, 69, 798. | 0.4 | 0 |
| 116 | Selection of the Best of 2016 in Clinical Cardiology: Continuum of Care; Relationship Between Cardiology and Primary Care. Revista Española De Cardiología (English Ed), 2017, 70, 122-123. | 0.4 | 0 |
| 117 | Selection of the Best of 2016 in Clinical Cardiology: Therapeutic Novelties. Revista Española De Cardiología (English Ed), 2017, 70, 123-124. | 0.4 | 0 |
| 118 | Selection of the Best of 2017 in Clinical Cardiology. Continuum Healthcare Between Cardiology and Primary Care. Revista Española De Cardiología (English Ed), 2018, 71, 59. | 0.4 | 0 |
| 119 | Cost-effectiveness of Evolocumab. Revista Española De Cardiología (English Ed), 2018, 71, 1089. | 0.4 | 0 |
| 120 | New Targets in Arterial Hypertension, Are They Justified?. Revista Española De Cardiología (English Ed), 2018, 71, 608-611. | 0.4 | 0 |
| 121 | Quality of life, medication adherence and satisfaction with anticoagulant treatment (dabigatran vs) Tj ETQq1 1 0.784314 rgBT /Overl Journal of Clinical Practice, 2020, 74, e13605. | 0.8 | 0 |
| 122 | First national registry of evolocumab in clinical practice in cardiology units in Spain. The RETOSS-CARDIO study. Revista Española De Cardiología (English Ed), 2020, 73, 513-515. | 0.4 | 0 |
| 123 | Telematic cardiology consultation in the elderly. The 5 M framework can help. Response. Revista Española De Cardiología (English Ed), 2021, 74, 118. | 0.4 | 0 |
| 124 | Telemedicine for patients with valvular heart disease or aortic disease in the era of COVID-19. Response. Revista Española De Cardiología (English Ed), 2021, 74, 362-363. | 0.4 | 0 |
| 125 | Soft skills in cardiology telemedicine consultations. Response. Revista Española De Cardiología (English Ed), 2021, 74, 563-564. | 0.4 | 0 |
| 126 | A new index to predict quality of anticoagulation control in patients on vitamin K antagonists: the DAFNE score. Future Cardiology, 2021, 17, 685-692. | 0.5 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Risk Alteration for Atrial Fibrillation with Different Antihypertensive Drugs. Journal of Atrial Fibrillation, 2011, 4, 423. | 0.5 | 0 |
| 128 | A new fastening system for temporary pacing with active-fixation leads: effectiveness and safety. European Heart Journal: Acute Cardiovascular Care, 2022, 11, 224-229. | 0.4 | 0 |
| 129 | Clinical and echocardiographic characteristics in patients with heart failure and type 2 diabetes. Future Cardiology, 2022, , . | 0.5 | 0 |